November 8, 2021 08:42 AM EST

Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration?

Kyle Blankenship

AstraZeneca and Daiichi Sankyo have struck gold as part of a high-dollar ADC collaboration, with Enhertu well on its way to blockbuster sales. But Daiichi’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration?

Kyle Blankenship

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Seagen and Dai­ichi are duk­ing it out over the link­ers used in some block­buster drug plays. Could that af­fect a high-dol­lar As­traZeneca col­lab­o­ra­tion?

Kyle Blankenship

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival